Kidney toxicity accounts both for the failure of many drug candidates as well as considerable patient morbidity. Whereas histopathology remains the gold standard for nephrotoxicity in animal systems, serum creatinine (SCr) and blood urea nitrogen (BUN) are the primary options for monitoring kidney dysfunction in humans. The transmembrane tubular protein kidney injury molecule-1 (Kim-1) was previously reported to be markedly induced in response to renal injury. Owing to the poor sensitivity and specificity of SCr and BUN, we used rat toxicology studies to compare the diagnostic performance of urinary Kim-1 to BUN, SCr and urinary N-acetyl--d-glucosaminidase (NAG) as predictors of kidney tubular damage scored by histopathology. Kim-1 outperforms SCr, BUN and urinary NAG in multiple rat models of kidney injury. Urinary Kim-1 measurements may facilitate sensitive, specific and accurate prediction of human nephrotoxicity in preclinical drug screens. This should enable early identification and elimination of compounds that are potentially nephrotoxic. a nephrotoxicity marker, relative to BUN, SCr and urinary NAG. To allow the generalizability and reproducibility of the results, rodent toxicology studies with unique and overlapping nephrotoxicants were conducted at two different sites, Novartis (Basel) and Merck Research Laboratories (West Point, New Jersey, USA). Using a clinically relevant model of bilateral renal ischemia/reperfusion injury to the kidney, we tested ten well-established nephrotoxicants, three hepatotoxicants and a cardiotoxicant to correlate the diagnostic performance of urinary Kim-1, BUN, SCr and urinary NAG with histopathology as a benchmark. Composite area under the receiver operating characteristics curve (AUC-ROC) analysis enabled us to evaluate the relative sensitivities and specificities of urinary Kim-1, BUN, SCr and NAG over subsets of histomorphologic scores using different ranges of severity grades. Our secondary objective involved testing a microbead-based assay for quantifying Kim-1 abundance, with the goal of increasing throughput of analyses involving this biomarker 20 . We conclude that the use of Kim-1 as a marker of nephrotoxicity could help to reduce the rate of attrition during clinical drug development, as well as aiding post-marketing surveillance of drug-related nephrotoxicity.
Acute kidney injury (AKI) is a common and devastating clinical problem with an in-hospital mortality of 40-80% in the intensive care setting 1 . Drug-induced nephrotoxicity plays a major role in the high incidence and prevalence of AKI in both hospitalized and nonhospitalized individuals 2 . Nephrotoxicity seen in animal toxicology studies is also a major factor in the failure of drug candidates because of the lack of good kidney biomarkers for monitoring kidney injury. Traditional markers of renal injury, SCr, BUN, urine sediment and urinary indices (e.g., fractional excretion of sodium and urine osmolality), lack the sensitivity and/or specificity to adequately detect nephrotoxicity before considerable loss of renal function. NAG, a proximal tubular brush border lysosomal enzyme, is released into the urine after renal proximal tubule injury and has been proposed to be a sensitive and robust indicator of kidney damage in rodents and humans [3] [4] [5] [6] [7] . Given "renal reserve" and each of the test's sensitivity, minimal histopathologic findings are often undetectable using these traditional biomarkers. There is thus an urgent need for improved and noninvasive renal biomarkers to permit early detection of AKI, assess the severity of injury, and aid in predictive safety assessment during drug development by resolving ambiguities associated between humans and animal test species 8 .
Kim-1 (also known as T cell immunoglobulin and mucin (TIM-1) and hepatitis A virus cellular receptor 1 (HAVCR-1)) is a type I cell membrane glycoprotein containing a unique six-cysteine immunoglobulin-like domain and a mucin-rich extracellular region that is conserved across species in zebrafish, rodents, dogs, primates and humans 9 . Kim-1 is a phosphatidylserine receptor on renal epithelial cells that recognizes apoptotic cells, directing them to lysosomes and thereby converting the normal proximal tubule cell into a phagocyte 10 . Kim-1 mRNA levels are elevated more than any other known gene across these species after initiation of kidney injury and the protein is localized at very high levels on the apical membrane of proximal tubule in that region where the tubule is most affected 9, 11 . After injury, the ectodomain of Kim-1 is shed from proximal tubular kidney epithelial cells into urine in rodents 3, 9, [11] [12] [13] [14] and humans 4, 5, 15, 16 . Urinary Kim-1 has been shown to be a sensitive and early diagnostic indicator of renal injury in a variety of acute and chronic rodent kidney injury models, resulting from drugs 3, 14, 17 , environmental toxicants 13, 14, 18 , ischemia 3 and protein overload 19 . However, studies thus far have lacked the ability to systematically evaluate the performance characteristics of urinary Kim-1 along with traditional biomarkers using different grades of histopathological damage as a benchmark of kidney damage.
The primary objective of this study was to comprehensively evaluate the relative sensitivity and specificity of urinary Kim-1 as Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies a nephrotoxicity marker, relative to BUN, SCr and urinary NAG. To allow the generalizability and reproducibility of the results, rodent toxicology studies with unique and overlapping nephrotoxicants were conducted at two different sites, Novartis (Basel) and Merck Research Laboratories (West Point, New Jersey, USA). Using a clinically relevant model of bilateral renal ischemia/reperfusion injury to the kidney, we tested ten well-established nephrotoxicants, three hepatotoxicants and a cardiotoxicant to correlate the diagnostic performance of urinary Kim-1, BUN, SCr and urinary NAG with histopathology as a benchmark. Composite area under the receiver operating characteristics curve (AUC-ROC) analysis enabled us to evaluate the relative sensitivities and specificities of urinary Kim-1, BUN, SCr and NAG over subsets of histomorphologic scores using different ranges of severity grades. Our secondary objective involved testing a microbead-based assay for quantifying Kim-1 abundance, with the goal of increasing throughput of analyses involving this biomarker 20 . We conclude that the use of Kim-1 as a marker of nephrotoxicity could help to reduce the rate of attrition during clinical drug development, as well as aiding post-marketing surveillance of drug-related nephrotoxicity.
RESULTS

Kim-1 gene and protein expression
We first used the Rat Genome 230 2.0 Array and Affymetrix Micro Array Suite 5.0 (MAS5) normalization to measure changes in Kim-1 gene expression in 48 organs/structures, blood and bone marrow obtained from control and high-dosed animals at various time points in numerous studies that included up to 45 active drug entities (many reference compounds and drugs known to be toxic to liver, cardiac, skeletal muscle, central nervous system, gastrointestinal, lung, bone and testis). Average raw intensity values and standard deviations for Kim-1 expression were very low ("absent" according to Affymetrix standards) across all organs analyzed in the control animals (baseline) (Supplementary Fig. 1) . Only blood cells, lymph nodes, spleen and lachrymal glands had reliably detectable baseline Kim-1 expression. The baseline level of Kim-1 was very low in kidney, and only after kidney toxicity, as detected by histopathology, was a >100-fold increase of Kim-1 expression evident (Fig. 1a) . Kim-1 expression did not change in any of the other organs demonstrating the specificity of Kim-1 for kidney injury (Supplementary Fig. 1 ). 
Figure 1
Correlation of Kim-1 mRNA and protein levels in the kidney and urine, and comparison of urinary Kim-1 levels with SCr, BUN and urinary NAG with severity grades of histopathology following a dose response and time course in ten Novartis rat toxicology studies. (a-c) Male Han Wistar rats (n = 739) were dosed with a low, medium or high dose of eight mechanistically distinct nephrotoxicants and two hepatotoxicants, and renal Kim-1 mRNA (a), renal Kim-1 protein (b) and urinary Kim-1 protein levels (c) were measured. (d-f) Conventional markers for kidney toxicity including SCr (d), BUN (e) and urinary NAG (f) were also measured and compared to different grades of kidney tubular histopathology. All values are represented as foldchanges versus the average values of study-matched and time-matched control animals on a logarithmic scale. The animals are ordered by study, within each study by dose group (with increasing doses) and within each dose group by termination time point (with increasing time). The symbols and the colors represent the histopathology readout for proximal tubular damage (red = no histopathology finding observed, green = grade 1, blue = grade 2, black = grade 3 on a 5-grade scale). For each toxicant the animals are ordered left to right by dose group (low to high). For each dose the animals are ordered from left to right by termination time point. The magenta lines represent the thresholds determined for 95% specificity in the ROC analysis for all histopathology grades. ANIT, α-naphthyl isothiocyanate.
A r t i c l e s
A dose-response and time-course study involving eight nephrotoxicants and two hepatotoxicants confirmed that Kim-1 gene expression (Fig. 1a) in the kidney was correlated with Kim-1 protein levels in the kidney (Fig. 1b) and urine (Fig. 1c) . These studies were conducted at Novartis using gentamicin, cisplatin (Platinol), vancomycin (Vancocin) and tacrolimus (Protopic, Prograf), all proximal tubular toxicants; puromycin and doxorubicin (Doxil, Adriamycin), both glomerular toxicants; furosemide (Lasix) and lithium (Eskalith), both tubular and collecting duct toxicants; and the two hepatotoxicants α-naphthyl isothiocyanate and methapyrilene.
We developed a microbead-based assay to measure Kim-1 protein using a pair of epitopically distinct mouse monoclonal antibodies against rat Kim-1 ectodomain. An important advantage of the microbead-based assay over previously established enzyme-linked immunosorbent assay (ELISA) methods 3 is the expanded dynamic range (from 4 pg/ml to 40,000 pg/ml), which eliminates the need to dilute the urine samples. Other advantages of this assay include the ability to quantify Kim-1 using only 30 µl of undiluted urine samples and reducing the assay time from 6 h to 3.5 h, while maintaining interand intra-assay variability between Kim-1 values <10%.
We compared levels of Kim-1 mRNA and protein in kidney and urinary Kim-1 protein levels for each animal (Fig. 1a-c) and observed a high degree of correlation between all three entities, as estimated by Pearson correlation (Supplementary Table 1 ). Kim-1 mRNA correlated significantly with Kim-1 protein in the kidney (r = 0.89) and urinary Kim-1 (r = 0.83). The correlation between Kim-1 protein in the kidney versus urine was also high and significant (r = 0.82).
Urinary and serum biomarker elevations after exposure to nephrotoxicants and hepatotoxicants
The standard for determination of kidney injury in the rat is careful microscopic examination of kidney morphology by a trained pathologist. The Critical Path Institute's Predictive Safety Testing Consortium (PSTC) Nephrotoxicity Working Group (NWG) 21 created a histopathology lexicon and assigned a severity score grading scale of 0-5 to grade pathological lesions from 0 (no observable pathology), 1 (minimal), 2 (slight), 3 (moderate), 4 (marked) or 5 (severe) 22 . We measured urinary Kim-1, SCr, BUN and urinary NAG from 132 nephrotoxicant-dosed animals with tubular injury (grade 1-3 on a 5-grade scale) and from 283 vehicle-dosed animals without proximal tubular injury (Fig. 1c-f) . We further included biomarker values for 324 dosed animals showing either no lesion or other lesions (e.g., fibrosis) or lesions in other parts of the kidney, apart from the proximal tubule thereby including a total of 739 animals in our analysis. In all cases urinary Kim-1 and urinary NAG were normalized to urinary creatinine concentration.
A statistical analysis of the data from all of the studies shows that urinary Kim-1 outperformed SCr, BUN and NAG in terms of early detection, sensitivity and specificity. The highest number of nephrotoxicant-treated animals scoring above the 95% specificity threshold was identified by urinary Kim-1 (79%) whereas BUN, SCr and urinary NAG identified 52%, 44% and 52% respectively, of animals with proximal tubular injury ( Fig. 1d-f) . Especially for the cisplatin, gentamicin and vancomycin studies, urinary Kim-1 was elevated in nearly all animals with proximal tubular injury (88%) in contrast to BUN, urinary NAG and SCr, which displayed 42%, 42% and 40% of true positives, scored by histopathology. Ten of the very few Kim-1 false-negative animals had predominantly grade 1 lesions (e.g., one animal in the cisplatin study, five animals in the gentamicin study, two animals in the puromycin study and two animals in the doxorubicin study). The only drug displaying an above average number of grade 1 false-negative animals (14) was furosemide, which is known to induce tubular degeneration and/or necrosis in the S3 segment. However, with furosemide, as with other toxicants, Kim-1 kidney mRNA and protein levels appear elevated. The other markers, except for BUN (Fig. 1e) , showed a performance similar to Kim-1 for the furosemide study. The tacrolimus-induced proximal tubular lesions was identified only by Kim-1 (Fig. 1c) . High-dose lithium resulted in kidney lesions described as collecting duct necrosis and this resulted in significant elevation of urinary NAG. There was no increase in BUN, SCr or Kim-1, consistent with no proximal tubular histopathology change. In both hepatotoxicant studies, levels of Kim-1, NAG and BUN were unchanged as compared to controls. This was in agreement with histopathology assessment, which did not reveal any hepatotoxicant-induced kidney lesions. In contrast, SCr levels increased after a high dose of the hepatotoxicant α-naphthyl isothiocyanate, with negative kidney histopathology indicating nonspecificity of SCr, especially in the context of muscle breakdown in this study.
Composite sensitivity and specificity of urinary Kim-1, urinary NAG, BUN and SCr correlating to histopathology in kidney injury for eight nephrotoxicants We used AUC-ROC as the metric for statistical assessment of relative performance, as it is easily interpreted and permits statistical evaluation of whether one marker outperforms another. In the 'exclusion' analysis, only samples from animals not treated with a nephrotoxicant and samples from animals treated with nephrotoxicants that developed histopathologic lesions were considered. Specifically, samples from animals given known nephrotoxicants that did not display kidney histopathology were excluded. All samples were considered in the 'inclusion' analysis 22 . Exclusion analysis sets aside data values that show discordance between histopathology and early biomarker values in nephrotoxicant-treated animals. In contrast, the inclusion approach assumes that discordance between early biomarker values and true injuries may be attributed to false-positive biomarker values.
The results of the ROC analysis ( Table 2 ). Statistical tests using ROC analysis confirmed that Kim-1 outperformed NAG, SCr and BUN (P < 0.001, using both the exclusion and inclusion methods for data analysis (Supplementary Table 3) ). For low-grade histopathology (grade 1 versus grade 0) Kim-1 maintained high diagnostic performance (AUC of 0.88 by exclusion analysis) whereas urinary NAG, BUN and SCr performed poorly with AUC values (all exclusion analysis) of 0.8, 0.76 and 0.67, respectively (Fig. 2c,d) . The low sensitivity of BUN and SCr for detection of kidney injury has been recognized for a number of decades. Our data clearly confirm this, with a sensitivity of 0.48 for BUN, and 0.29 for SCr when there was subtle proximal tubular damage (grade 1 versus 0) following kidney toxicity. The sensitivity of urinary Kim-1 remained high both when the proximal tubular damage was subtle (grade 1 versus 0; sensitivity of 0.71) and when injury was a little more severe (grade 2 versus 0; sensitivity of 0.79) (Fig. 2e) .
Urinary and serum biomarker elevations with gentamicininduced nephrotoxicity
The following set of studies were conducted at Merck using two of the nephrotoxicants (gentamicin and cisplatin) used in the studies conducted at Novartis and two unique nephrotoxicants (cyclosporine A and thioacetamide). Elevations in urinary Kim-1 were closely correlated with gentamicin-induced damage to kidney tubules detected by histopathology. On days 9 and 15 of treatment, mid-dose (80 mg/ kg/d)-treated animals showed mean normalized urinary Kim-1 levels that were elevated 11-and 40-fold, respectively, compared to mean concurrent control values. High-dose (240 mg/kg/d)-treated animals on days 3, 9 and 12 showed 23-, 117-, 163-fold increased levels of urinary Kim-1, respectively (Fig. 3) . Tubular degeneration, necrosis and regeneration observed at days 9 and 12 in animals treated with high-dose gentamicin corresponded to an ~100-fold elevation of urinary Kim-1. By comparison, lower doses (20 mg/kg/d) were associated with a lower incidence and severity of tubular degeneration, necrosis and regeneration, as well as smaller elevations in Kim-1 levels at 20 mg/kg/d at day 15, or at 80 mg/kg/d as early as day 3, which persisted to days 9 and 15. After treatment with the high dose of gentamicin, normalized NAG activity was elevated nearly tenfold on day 3 ( Fig. 3) . At days 12 and 15, NAG activity levels were elevated for the mid-and high-dose animals, with corresponding histomorphologic severity grades of 2 and 5, respectively (Fig. 3) .
Only animals treated with the high dose showed markedly elevated SCr levels >1.5 mg/dl at day 9, but SCr levels were normal at day 3. Similarly, BUN elevations were seen only in high-dose animals at day 9.
Urinary and serum biomarker elevations with cisplatin-induced nephrotoxicity Normalized urinary Kim-1 levels were elevated after mid-dose (3.5 mg/kg) treatment with cisplatin at both days 3 and 8 (20-and 97-fold, respectively), where severity grade 2 and 4 overall tubular damage scores were observed (Fig. 4) . Similarly, normalized urinary Kim-1 was elevated in high-dose (7 mg/kg) cisplatin-treated animals both at day 3 (11-fold) and day 8 (48-fold), corresponding with severity grade 2 and 5 overall tubular damage scores, respectively (Fig. 4) . A mean increase of approximately ninefold was seen in low dose (0.5 mg/kg) animals at day 3, which trended down at day 8. With cisplatin treatment, normalized NAG values were elevated over twofold at day 3 in animals showing tubular grade 2 overall tubular damage at the high dose, but not in animals with grade 2 overall tubular damage at the mid-dose. At day 8, urinary NAG activity did not change in mid-and high-dose-treated animals with severity grade 4 to 5 overall tubular damage (Fig. 4) . There were treatment-related increases in BUN and SCr in the mid-and highdose treatment groups at both days 3 and 8 with markedly higher elevations for both at day 8 after high-dose treatment.
Urinary and serum biomarker elevations after nephrotoxicity induced by cyclosporine A and thioacetamide
For rats treated with 0, 6, 30 or 60 mg/kg/d cyclosporin A for 3, 9 or 15 d, we observed subtle tubular basophilia of the regenerative type at severity grades 1 and 2 in most mid-dose animals at day 15, (a-e) ROC curves from eight different nephrotoxicant studies and two different hepatotoxicant studies from Novartis, demonstrating sensitivity and specificity of BUN, SCr, urinary Kim-1 and NAG with respect to a composite histopathology score that included all histopathology grades (a), histopathology grade 0 to 2 (b) and histopathology grade 0 to 1 (c). (d,e) Area under the curve (d) and sensitivity (e) (at 95% specificity) compared to the 'gold standard', histopathology. Urinary Kim-1 and NAG were normalized to urinary creatinine. Animal numbers, n. Negative: n = 283. Positive: all, n = 132; 0 to 2, n = 129; 0 to 1, n = 94. Fig. 2 ). Elevations of Kim-1 were seen in all animals with histomorphologic changes (Supplementary Fig. 2 ), whereas elevated NAG activity was seen in nearly half of the animals with tubular regeneration. With cyclosporin A treatment, modest elevations in BUN were observed in all animals with histomorphologic changes on day 15 after high-dose treatment. In contrast, we did not observe increases in SCr associated with histomorphologic changes. Thioacetamide (TAA) has been reported as a model nephrotoxicant of proximal tubule injury 23 . A 2-and 3-d TAA study was performed using single administrations of either 50, 100 or 200 mg/kg (Supplementary Fig. 3 ). We observed both liver and kidney histomorphologic changes, including tubular degeneration and necrosis, at all doses and on both days. The observed tubular histopathologic changes were severity grade 1 and 2 for day-2 animals and increased in a dose-dependent manner on day 3. Urinary Kim-1 levels was the most sensitive biomarker of toxicity, with 34-and 36-fold increases in concentration at days 2 and 3, respectively, already seen with low-dose treatment ( Supplementary  Fig. 3 ). At the mid-dose, Kim-1 levels were increased 12-and sixfold at days 2 and 3, respectively, and about 18-fold at the high dose on both days. Urinary NAG activity increased in a dose-dependent manner at both days 2 and 3 ( Supplementary Fig. 3 ). Significant elevations in BUN and SCr were observed only on day 3 after midand high-dose treatment (P < 0.05).
Sensitivity and specificity of urinary Kim-1 and NAG, BUN and SCr with respect to kidney histopathology caused by four nephrotoxicants The performance of Kim-1 in the Merck studies as measured by AUC from the ROC analysis (Fig. 5 and Supplementary Table 2 ) was consistently high (>0.99 by exclusion analysis and >0.96 by inclusion analysis) for all of the histomorphologic severity grade subsets (Fig. 5a,e) (Supplementary Table 2) . For the analysis that uses all of the samples, the difference in AUC between Kim-1 and NAG was 0.12 by both exclusion and inclusion analyses (P < 0.001). The difference in AUC between Kim-1 and SCr was 0.15 by exclusion analysis (P < 0.001) and 0.10 by inclusion analysis (P < 0.001) and the difference in AUC between Kim-1 and BUN was 0.09 by exclusion analysis (P < 0.001) and 0.12 by inclusion analysis (P < 0.001) (Supplementary Table 3) . The difference in AUC between Kim-1 and NAG increased from 0.12, when all nephrotoxicity samples were used, to 0.26, when those with a severity grade 0 and 1 were used; between Kim-1 and BUN it increased from 0.09, using all nephrotoxicity samples, to 0.22, using only the severity grade 0 and 1 nephrotoxicity sample subsets. This indicates a lower correlation of NAG and BUN to histomorphologic change when a more sensitive morphologic metric was employed (Fig. 5a,d,e) . Similarly the difference in AUC between Kim-1 and SCr increased from 0.15, using all nephrotoxicity samples, to 0.37, using only the severity grade 0 and 1 nephrotoxicity sample subsets (Fig. 5a,d,e) . The sensitivity, or proportion of positives correctly identified at a threshold that yields 95% specificity, for Kim-1 was 0.99 for all of the nephrotoxicity histopathology severity grade subsets (Fig. 5a,d,f) . The sensitivity for NAG decreased from 0.56 using all nephrotoxicity samples to 0.20 for severity grade 0 and 1 subset ( Fig. 5f and Supplementary Table 2) . Similarly the sensitivity for BUN and SCr also decreased from 0.71 and 0.68, respectively, using all nephrotoxicity samples, to 0.45 and 0.20, respectively, using severity grade 0 and 1 nephrotoxicity sample subsets ( Fig. 5f and Supplementary Table 2 ). Both inclusion and exclusion analysis show that unlike BUN, SCr and NAG, the performance of Kim-1 is uniformly high within the full range of nephrotoxicity subsets analyzed (Supplementary Tables 2 and 3) .
Specificity of urinary Kim-1 as a biomarker for kidney injury
We measured urinary Kim-1 levels in well-established models of hepato-and cardiotoxicity at Merck to assess the specificity of increases in Kim-1 levels associated with renal damage. Bromotrichloromethane (CBrCl 3 ) induced substantial hepatotoxicity in rats on days 2 and 4 at both low and high doses, as assessed by plasma levels of alanine aminotransferase (ALT) aspartate aminotransferase (AST) proteins and histopathology scoring (necrosis and degeneration). Nonetheless, it produced no treatment-related kidney toxicity (Supplementary Table 4) . Urinary Kim-1 levels were similar between controls and CBrCl 3 -treated animals with liver injury. Isoproterenol induced necrosis and degeneration of both cardiac and skeletal muscle with histomorphologic changes at 3 and 8 d after a dose of 1 mg/kg/d, yet did not cause increases in urinary Kim-1 levels. Our observation that changes in urinary Kim-1 levels were unremarkable after toxicant-induced hepatotoxicity and cardiotoxicity in rats further supports the specificity of Kim-1 for renal damage (Supplementary Table 4) . 
A r t i c l e s
Comparison of urinary Kim-1 with other markers in the rat model of renal ischemia/reperfusion injury (I/R)
We used a rat model of 20-min bilateral renal I/R to show an approximately three-and sixfold increase in urinary Kim-1 as compared to sham 3 h and 6 h after reperfusion, respectively. Urinary Kim-1 levels peaked at 24 h (700-fold increase) and plateaued to levels persistently above baseline at 96 and 120 h (~70-fold increase) after reperfusion (Fig. 6) . This time course correlated with the histological changes of the kidney with grade 1 proximal tubular damage at 3 h and 6 h, and single cell necrosis, tubular dilation and sloughing of cells in tubules of the outer stripe of the outer medulla at 9 h after I/R. At 12 and 24 h there was substantial proximal tubular necrosis with associated inflammation and cast formation classified as grade 4 and 5 histopathology, respectively. Modest and transient elevations in BUN (~1.4 fold), SCr (~1.5 fold) and NAG (3.2 fold) were observed only at earlier time points (between 3 and 9 h) after reperfusion. Statistically significant increases in urinary NAG activity were observed at 12 h after reperfusion with ~5.5 fold elevation and at 18 h for BUN (~2.1 fold) and SCr (~2.4 fold) (Fig. 6) .
Threshold determination comparisons
For the purposes of obtaining uniformity in data interpretation, it is important that the thresholds derived from different biomarker study data sets for a specific predefined sensitivity or specificity should be the same for practical general utility. For the Novartis studies, ROC analysis defined a threshold for 95% specificity of 1.87-fold increase (by exclusion analysis and 3.9-fold by inclusion analysis) (Supplementary Table 2 ). For the Merck studies, ROC analysis defined a threshold for 95% specificity of 1.88-fold increase (Supplementary Table 2) . Similarly for SCr, the threshold cutoffs from the Novartis and Merck studies were 1.14-fold and 1.2-fold, for BUN 1.2 and 1.3-fold and for NAG 1.4 and 2.4 -fold, respectively. As the threshold for 95% specificity is mainly determined by the variance of the control animals, one can conclude that despite different rat strains, study designs and assay setups, the urinary Kim-1, SCr and BUN levels across control animals are highly reproducible, and the magnitude response necessary to signal that a significant deviation from normal equates to pathology is also consistent. Logistic regression models were fit to assess whether Kim-1 and NAG add information to models that rely on SCr and BUN. The results show that both Kim-1 and NAG provide substantial additional information (Supplementary Table 5 ). Using exclusion analysis with the binary logistic model on the Novartis data, the addition of Kim-1 was statistically significant (P < 1.0E-05) and increased the concordance probability (C, equivalent to AUC from ROC in this case) by 0.159, the R2 by 0.37 and IDI by 0.35. The P-value from a likelihood ratio test, the concordance probability, C 24 , an R2 25 statistic, and integrated discrimination improvement index, IDI 26 were used to evaluate the improvement gained by the addition of each marker to a model containing SCr 
Figure 6
Comparison of Kim-1 with routinely used biomarkers as an early diagnostic indicator of kidney injury after 20-min bilateral I/R. Male Wistar rats were subjected to 0 (sham) or 20 min of bilateral ischemia by clamping the renal pedicles for 20 min and then removing the clamps and confirming reperfusion. Two hours after reperfusion the rats were placed in metabolic cages and urine, blood and tissue collected at 3, 6, 9, 12, 18, 24, 48, 72, 96 and 120 h after reperfusion. Urinary Kim-1, BUN, SCr and urinary NAG were measured and these levels were correlated to histopathology (H&E staining). Open squares indicate grade 0 pathology and the composite tubular severity score is color coded yellow (1), orange (2), red (3), purple (4) and blue (5). A r t i c l e s and BUN. The addition of NAG for the SCr+BUN model was statistically significant (P < 1.0E-05) and increased C by 0.052, R2 by 0.105 and IDI by 0.08. For the Merck data, Kim-1 was statistically significant (P < 1.0E-05), and increased C by 0.059, R2 by 0.279 and IDI by 0.267. In the Merck data, NAG was statistically significant (P = 0.021) and increased C by 0.004, R2 by 0.028 and IDI by 0.019. Results from ordinal logistic regression tended to give similar results (Supplementary Table 5 ).
DISCUSSION
In an effort to evaluate the capacity of Kim-1 to identify nephrotoxicity, we compared the relative performance of four biomarkers to accurately assess kidney injury in eleven structurally and mechanistically different models of renal tubular injury in rats. Regardless of whether the kidney injury was induced by well-established kidney toxicants or ischemia, urinary Kim-1 outperformed BUN, SCr and urinary NAG, which are conventional markers for assessing renal injury. Moreover, the ROC-AUC values of 0.91 to 0.99 obtained for urinary Kim-1 demonstrate that urinary Kim-1 measurements are highly sensitive, specific and accurate in diagnosing either drug-induced kidney tubular necrosis, degeneration, and/or dilatation, as well as regenerative basophilia when lesions are either subtle with little organ involvement, or very severe with disturbed renal function. We further show by exclusion analysis that a threshold increase of 1.87-fold of urinary Kim-1 concentration for 95% specificity derived from one laboratory was similarly and independently defined in other laboratories using other study designs for kidney injury. In this set of 17 studies conducted at three sites, the increase in urinary Kim-1 was compared to histopathology, which is considered the best available benchmark for assessing preclinical renal injury. The AUC and the sensitivity of Kim-1 was nearly 1, irrespective of the mechanism of kidney injury and remained >0.9 whether the entire histopathology grade of 0 to 5 was included or whether the analyzed group was restricted to histopathology grade scores of 0 and 1. We demonstrate that current markers of assessing nephrotoxicity, BUN and SCr, are effective only with more severe histopathological grades (greater than grade 2) in preclinical studies. For example, the sensitivity of SCr was remarkably low at 0.20 for histology grades 0 to 1 and increased to only 0.56 with severity grades of 0 to 3 in the Merck studies. In contrast, urinary Kim-1 was sensitive and specific for assessing subtle forms of proximal tubular damage (histology grade 0 to 1). These AUC-ROC values represent the exclusion data analysis approach. Although generally both exclusion and inclusion analyses yielded similar comparative performance among the biomarkers, inclusion analysis approximately doubles the Kim-1 threshold indicative of injury to 3.9-fold higher thresholds, and thus lower sensitivity, than exclusion analysis for the same level of specificity (Supplementary Table 2) .
On the basis of the striking evidence of the performance of urinary Kim-1 as a highly sensitive and specific marker of drug-induced kidney injury, we made the following claims for the preclinical use of Kim-1 in the Voluntary eXploratory Data Submission we forwarded to the European Medicines Agency (EMEA) and US Food and Drug Administration (FDA). (i) Urinary Kim-1 can outperform and add information to BUN and SCr as an early diagnostic biomarker of drug-induced acute kidney tubular alterations in rat toxicology studies. (ii) Urinary Kim-1 is qualified for regulatory decision making as a biomarker that may be used by sponsors on a voluntary basis to demonstrate that drug-induced acute kidney tubular alterations are monitorable in good laboratory practice rat studies, which are used to support the safe conduct of clinical trials. (iii) Urinary Kim-1 can be considered qualified for regulatory decision making as a clinical bridging biomarker appropriate for use by sponsors on a voluntary basis in phase 1 and 2 clinical trials for monitoring kidney safety when animal toxicology findings generate a concern for tubular alterations.
Both FDA and EMEA agreed on the preclinical claims. Moreover, because of the potential clinical utility of KIM-1, both agencies proposed the use of Kim-1 as a translational safety biomarker on a caseby-case basis under certain mutually agreeable conditions.
Human studies have yielded promising results for potential utility of urinary KIM-1 as a diagnostic biomarker for AKI. One study showed marked expression of KIM-1 in kidney biopsy specimens from six patients with acute tubular necrosis and elevated urinary levels of KIM-1 after an initial ischemic renal insult before the appearance of casts in the urine 15 . Another showed urinary KIM-1 and NAG in 201 patients with established AKI and demonstrated that elevated levels of urinary KIM-1 and NAG were significantly associated with the clinical composite endpoint of death or dialysis requirement, even after adjustment for disease severity or comorbidity 4 . Researchers compared the tissue expression of KIM-1 with histopathological and functional parameters of acute tubular injury (ATI) and acute cellular rejection (ACR) in renal transplant biopsies from 62 patients 27 . KIM-1 expression was present in all biopsies from patients with histological changes showing ATI and in 92% of kidney biopsies from patients with ACR. KIM-1 staining sensitively and specifically identified proximal tubular injury and significantly correlated with declining renal function. A longitudinal prospective study reported that elevated urinary KIM-1 serves as an independent predictor of long-term graft loss in renal transplant recipients (n = 145 patients) independent of donor age, creatinine clearance and proteinuria 16 . In a study comparing nine urinary biomarkers (KIM-1, NGAL, IL-18, NAG, protein, HGF, VEGF, IP-10 and cystatin C) in 204 patients with or without acute kidney injury, we showed that urinary KIM-1 had an AUC-ROC of 0.93 and was significantly higher in patients who progressed either to death or to requirement for renal replacement therapy (RRT) when compared to those who survived and did not require RRT 5 . More recently, we have also reported the development of a rapid point-of-care diagnostic dipstick assay for measuring Kim-1 in rodent and human urine samples within 15 min 28 . Qualification of KIM-1 as a biomarker for clinical applications will involve a systematic evaluation of the diagnostic performance of KIM-1 in well-controlled observational and/or interventional clinical protocols using both standard-of-care agents with known nephrotoxic properties and/or exploratory agents with renal safety concerns. The opportunity to use the same translational marker such as Kim-1 for both the preclinical and clinical setting facilitates clinical monitoring of toxicity that has been demonstrated at higher doses in preclinical development or in a single test species when human relevance is suspected.
In summary, we report that urinary Kim-1 levels correlate with different grades of kidney tubular histopathologies in 11 well-established rat models of acute kidney injury. Using either exclusion or inclusion data analysis, Kim-1 had the highest AUC-ROC (>0.88) when compared with BUN, SCr and NAG. Especially for low-grade toxicity (grade 1), Kim-1 was the only marker of the four capable of consistently detecting renal tubular injury. Urinary Kim-1 outperformed (P < 0.01) SCr, BUN and urinary NAG as biomarkers of renal tubular injury in these mechanistically distinct models of kidney injury performed at three different sites. Binary and ordinal logistic regression models for exclusion and inclusion data analysis showed that addition of Kim-1 represented a statistically significant improvement and increased the concordance probability to histopathology.
A r t i c l e s
Thus, urinary Kim-1 measurement is anticipated to significantly aid in the prediction of human nephrotoxicity during preclinical studies by early identification, monitoring and elimination of compounds that are potentially nephrotoxic and may also allow nephrotoxicity to be monitored in humans.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
ONLINE METhODS
Animals. Male HAN Wistar rats (275-300 g) and male Sprague Dawley (SD) rats (275-325 g) were purchased from Harlan and maintained in central animal facility over wood chips free of any known chemical contaminants under conditions of 21 ± 1 °C and 50-80% relative humidity at all times in an alternating 12 h light-dark cycle. Rats were fed with commercial rodent chow (Teklad rodent diet no. 7012), given water ad libitum and were acclimated for 1 week before use. All animal maintenance and treatment protocols were in compliance with the Guide for Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health and were approved by respective Institutional Animal Care and Use Committees (IACUC).
Experimental design. Novartis Studies. Ten studies using HAN Wistar rats dosed with eight nephrotoxicants and two hepatotoxicants were conducted to generate dose-and time-dependent nephrotoxicity and hepatotoxicity. All studies followed a specific generic study design. For specific differences, such as differences in termination time points, see Supplementary Table 6 . Three groups of 24 Wistar Han males (11-12 weeks old) per study group received daily the test item, at the three different dose levels listed in Supplementary  Table 6 . An additional group of 24 males received the vehicle under the same experimental conditions and acted as a control group. The animals were checked daily for mortality and clinical signs. Body weight and food consumption were recorded regularly during the study. Urine was collected for urinalysis and biomarker measurement as described below. For the termination time point day 1 no urine was collected, and for some animals not enough urine for all investigations was obtained. In total, 739 samples were available for urinary biomarker analysis. On completion of the treatment periods, six non-fasted animals per group at each time point (four termination time points) were sampled 3 h after dosing for laboratory investigations (blood biochemistry, urinalysis and histopathology). The animals were euthanized and examined macroscopically post-mortem. Designated organs (kidneys, liver and brain) were weighed and specified tissues preserved. The kidneys and liver were processed using conventional methods for histological assessment. The right kidney of all dose groups and the liver of all animals of the control and high-dose groups and additionally of the low-dose and mid-dose groups for the two hepatotoxicant studies were examined microscopically after H&E staining. Histopathology of the kidneys was evaluated according to the Predictive Safety Testing Consortium Nephrotoxicity Working Group (PSTC NWG) histopathology lexicon and scoring system. All studies were performed at Centre International de Toxicologie (CIT) (BP 563, 27005 Evreux, France) in compliance with animal health regulations, in particular with the Council Directive No. 86/609/EEC of 24th November 1986.
Merck Studies. Male Sprague Dawley rats received one of four nephrotoxicants (gentamicin, cisplatin, thioacetamide or cyclosporine), or one well-established hepatotoxicant (carbon tetrachloride), or one well-established cardiotoxicant (isoproterenol) for sensitivity and specificity studies. Gentamicin sulfate was administered at 0, 20, 80 or 240 mg/kg/d (n = 5 rats/dose group/time point) and the animals were necropsied on days 3, 9 or 15 for toxicity evaluation, which included serum clinical chemistry (BUN, SCr), analysis of urine Kim-1 and NAG and histomorphologic evaluation of kidneys (H&E staining), as described below. The 240 mg/kg/d gentamicin sulfate day 15 group was terminated early at treatment day 12 due to physical signs of animal distress. In the cisplatin groups a single dose of cisplatin was administered intraperitoneally (i.p.) to male Sprague Dawley rats (n = 5 rats/dose group/time point) at doses of 0, 0.5, 3.5 or 7 mg/kg/d and necropsy was performed on day 3 or 8 post-treatment. Cyclosporine A was administered subcutaneously (s.c.) at 0, 6, 30 or 60 mg/kg/d to rats (n = 5/dose/time point) and necropsy was performed on day 3, 9 or 15. A single dose of TAA was administered by oral gavage at 0, 50, 100 or 200 mg/kg (n = 5 rats/dose group/time point) and necropsy was performed on day 2 (24 h post-dose) or day 3 (48 h post-dose). CBrCl3 was administered orally (p.o.) at 0, 0.03, 0.1 ml/kg to rats (n = 5/dose/time point) and necropsy was performed on day 2 or 4. Isoproterenol was administered intravenously (i.v.) at 0, 0.064, 0.25, or 1 mg/kg/day to rats (n = 5/dose/time point) and necropsy was performed on day 3 or 8.
Renal ischemia-reperfusion studies. Eighty male Wistar (W) rats weighing ~270-300 g were anesthetized with an intraperitoneal injection of pentobarbital sodium (30 mg/kg) and placed on a homeothermic table to maintain core body temperature at 37 °C, by means of a rectal probe attached to a temperature regulator, which was in turn attached to a homeothermic blanket. A midline laparotomy was made, renal pedicles were isolated and bilateral renal ischemia was induced by clamping the renal pedicles for 0-20 min as described previously 3 . Occlusion was verified visually by change in the color of the kidneys to a paler shade and reperfusion by a blush. Reperfusion commenced when the clips were removed. The rats were divided into groups of six rats each after 3, 6, 9, 12, 18, 24, 48, 72, 96 and 120 h of reperfusion. Rats (n = 4) per group were immediately placed in metabolic cages at 22 °C. Individual urine samples were collected at 3, 6, 9, 12, 18, 24, 48, 72, 96 and 120 h after reperfusion. Urinary NAG (Roche Diagnostics) was measured spectrophotometrically 3 and urinary Kim-1 was measured using the xMAP Luminex technology described below. Another set of rats (n = 4) was euthanized by overdose of pentobarbital (200 mg/kg, i.p.) at 3, 6, 9, 12, 18, 24, 48, 72, 96 and 120 h after reperfusion. Blood was collected from the dorsal aorta in heparinized tubes for measurement of BUN and SCr. One kidney was perfused through the left ventricle with PBS and then with paraformaldehyde lysine periodate for 10 min for histology.
Urine collection. Novartis studies. Urine was collected, from 2:00-8:00 p.m. and from 8:00 p.m. to 6:00 a.m. on the days listed in Supplementary Table 6 from fasted animals, into tubes and kept at ~4 °C during the collection period. The sampled urine fractions were split in 2-ml aliquots and centrifuged at 4 °C for 30 min at 10,000g. Urinalysis and urinary biomarker analysis (separate aliquot) were subsequently performed on the urine samples collected overnight. Urine analyses were performed with an Advia 1650 analyzer. For the termination time-point day 1, no urine was collected and for some animals not enough urine for all investigations was obtained. In total, 739 samples for urinary biomarker analysis were available.
Merck studies. Urine was collected before necropsy (18 h ± 2 h collection period) and the rats were placed in standard metabolic cages and fasted before collection. Urine samples were collected from individual animals into containers surrounded by dry ice and were stored at −80 °C until being thawed for urinalysis. After the initial thawing at 22 °C, samples were placed on wet ice and volume measurement was performed (precipitates were allowed to settle by gravity and were discarded). Typically, 2.5-ml urine samples was used for routine clinical chemistry urinalysis (Roche Modular Analyzer): manual specific gravity, pH, protein, glucose, SCr, occult blood, SCr and ketones were measured (only Scr shown). For the remaining urine volumes, small aliquots were made and stored at -80 °C until biomarker analysis to avoid repeated freeze-thaw cycles.
Blood collection and clinical chemistry. Novartis studies. On completion of the treatment periods, six non-fasted animals per group at each time point (four termination time points) were sampled for laboratory investigations (blood biochemistry, urinalysis and histopathology) 3 h after dosing. The maximum blood volume (at least 5 ml) was taken immediately before scheduled necropsy, from the retro-orbital sinus of the animals, under light isoflurane anesthesia, and collected into tubes. The tubes for determination of plasma levels of the test item were placed before and after blood sampling in wet ice. The blood sampling was split for (i) RNA extraction: 1 ml into Fastubes; (ii) Blood biochemistry: 0.7 ml into a lithium heparin tube and (iii) Biomarker assays: the remaining blood was collected into sodium EDTA tubes. Clinical chemistry analyses of urine and blood were performed with an Advia 1650 device for measuring BUN (using Urease UV from Bayer) and creatinine (using Jaffe from Bayer).
Merck studies. Rats were fasted overnight before necropsy and bled from the vena cava with 2 ml collected into a serum separator tube and centrifuged 1,500g for 10 min at 4 °C. An additional 2 ml of collected blood was placed into an EDTA collection tube and centrifuged 900g for 15 min at 4 °C to isolate plasma. Isolated plasma and serum samples were stored at −80 °C until use. BUN (mg/dl) and creatinine were measured using a standard clinical chemistry analyzer (Roche-Modular). AST (aspartate aminotransferase) (IU/L), ALT (alanine aminotransferase) (IU/L), alkaline phosphatase (IU/L) and creatinine kinase (IU/L) were measured using the same clinical chemistry analyzer for isoproterenol and CBrCl 3 toxicity studies.
